R. C. Brito

Immunoinformatics Features Linked to Leishmania Vaccine Development: Data Integration of Experimental and In Silico Studies

João P. L. Velloso, F. G. Guimarães, J. Ruiz, 2017, International journal of molecular sciences.

Chimeric Vaccines Designed by Immunoinformatics-Activated Polyfunctional and Memory T cells that Trigger Protection against Experimental Visceral Leishmaniasis

J. Ruiz, R. Corrêa-Oliveira, A. B. Reis, 2020, Vaccines.

Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis

E. S. Coimbra, D. Menezes-Souza, B. M. Roatt, 2021, Medical Microbiology and Immunology.

In vitro and in vivo antileishmanial activity of β-acetyl-digitoxin, a cardenolide of Digitalis lanata potentially useful to treat visceral leishmaniasis

R. Pádua, F. Braga, E. S. Coimbra, 2021, Parasite.

Ivermectin presents effective and selective antileishmanial activity in vitro and in vivo against Leishmania infantum and is therapeutic against visceral leishmaniasis.

E. S. Coimbra, B. M. Roatt, Grasiele S. V. Tavares, 2020, Experimental parasitology.

Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis

R. Pádua, F. Braga, E. S. Coimbra, 2020, Parasitology research.

Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis.

A. B. Reis, F. Frézard, R. D. O. Aguiar-Soares, 2021, Molecular Immunology.

Phase I and II Clinical Trial Comparing the LBSap, Leishmune®, and Leish-Tec® Vaccines against Canine Visceral Leishmaniasis

R. Corrêa-Oliveira, A. B. Reis, R. D. O. Aguiar-Soares, 2020, Vaccines.